Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GenusCHIX:GNSL -2.61%72 Return-on-Tangible-Equity is 17.84% as of Dec. 2025, which is 60% above its 10-year median of 11.17. GuruFocus rates CHIX:GNSL with a GF Score™ of 72/100 and a GF Value™ of £20.63 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Genus ranks better than 88.82% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Genus's annualized net income for the quarter that ended in Dec. 2025 was £59.6 Mil. Genus's average shareholder tangible equity for the quarter that ended in Dec. 2025 was £334.1 Mil. Therefore, Genus's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 17.84%.
The historical rank and industry rank for Genus's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:GNSl'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 2.22 Med: 11.17 Max: 26.11
Current: 14.05
During the past 13 years, Genus's highest Return-on-Tangible-Equity was 26.11%. The lowest was 2.22%. And the median was 11.17%.
CHIX:GNSl's Return-on-Tangible-Equity is ranked better than 88.82% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs CHIX:GNSl: 14.05
Genus (CHIX:GNSl) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Genus Return-on-Tangible-Equity Related Terms
Genus Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Genus's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GNSL vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Genus's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Genus's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 17.84% mean?
Genus (CHIX:GNSL) has a Return-on-Tangible-Equity of 17.84% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genus and its competitors. This is 60% above median its historical median of 11.17. Over the past decade, Genus' Return-on-Tangible-Equity has ranged from 2.22 to 26.11. According to the industry distribution chart, Genus ranks #134 out of 1199 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Genus' Return-on-Tangible-Equity too high?
Genus' current Return-on-Tangible-Equity of 17.84% is 60% above median its 10-year median of 11.17. Over the past 10 years, this metric has ranged from a low of 2.22 to a high of 26.11. Based on the distribution chart, Genus ranks #134 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genus has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genus' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #134 out of 1199 companies for Return-on-Tangible-Equity. This places Genus in the top 11% of its industry — outperforming the majority of peers. Historically, Genus' own Return-on-Tangible-Equity has ranged from 2.22 to 26.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Genus and its competitors. Genus's current Return-on-Tangible-Equity is 17.84%, which is 60% above median its own 10-year median of 11.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Based on GuruFocus' analysis, Genus (CHIX:GNSL) is currently considered Fairly Valued. The stock's GF Value™ is £20.63, compared to a current price of £21.31 — trading 3.3% above its estimated fair value. The current Return-on-Tangible-Equity is 17.84%, which is 60% above median its 10-year median of 11.17. Genus' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Genus (CHIX:GNSL), the current Return-on-Tangible-Equity is 17.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (CHIX:GNSL) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of £21.31 is trading 3.3% above its estimated GF Value™ of £20.63.
GuruFocus considers Genus to be Fairly Valued.
Key valuation signals for CHIX:GNSL:
Return-on-Tangible-Equity: 17.84% (60% above median its 10-year median of 11.17)
GF Value™: £20.63 vs. price of £21.31 (3.3% above fair value)
No single metric tells the full story. See the CHIX:GNSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
72GF Score
Get the complete analysis for CHIX:GNSL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GNSL has been successfully added to your 
